Two Sigma Investments LP Purchases New Shares in Q32 Bio Inc. (NASDAQ:QTTB)

Two Sigma Investments LP acquired a new position in Q32 Bio Inc. (NASDAQ:QTTB) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 53,175 shares of the company’s stock, valued at approximately $183,000. Two Sigma Investments LP owned approximately 0.44% of Q32 Bio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Acorn Capital Advisors LLC acquired a new stake in Q32 Bio in the 4th quarter valued at about $2,764,000. Monaco Asset Management SAM acquired a new position in Q32 Bio during the 4th quarter worth $1,977,000. Sanofi bought a new position in Q32 Bio in the 4th quarter valued at $840,000. Trustees of Columbia University in the City of New York bought a new position in Q32 Bio in the 4th quarter valued at $461,000. Finally, Mariner LLC acquired a new stake in shares of Q32 Bio in the 4th quarter valued at $418,000. Institutional investors and hedge funds own 31.32% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company cut their price target on Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 12th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $24.71.

Q32 Bio Price Performance

QTTB opened at $1.70 on Friday. The company has a fifty day moving average price of $1.75 and a two-hundred day moving average price of $4.15. The firm has a market capitalization of $20.74 million, a PE ratio of -0.12 and a beta of -0.03. Q32 Bio Inc. has a 52 week low of $1.38 and a 52 week high of $53.79. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53.

Q32 Bio (NASDAQ:QTTB) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.33. As a group, analysts anticipate that Q32 Bio Inc. will post -12.32 earnings per share for the current year.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.